恩华药业
(002262)
| 流通市值：209.49亿 | | | 总市值：240.74亿 |
| 流通股本：8.84亿 | | | 总股本：10.16亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,783,397,625.56 | 1,766,578,746.14 | 2,082,237,101.86 | 1,416,389,329.18 |
| 交易性金融资产 | 2,183,000,000 | 1,925,000,000 | 1,912,000,000 | 2,373,000,000 |
| 应收票据及应收账款 | 1,523,070,678.11 | 1,652,807,186.11 | 1,686,308,379.4 | 1,490,227,895.85 |
| 应收账款 | 1,523,070,678.11 | 1,652,807,186.11 | 1,686,308,379.4 | 1,490,227,895.85 |
| 应收款项融资 | 124,719,815.04 | 129,551,372.06 | 31,759,290.55 | 6,185,137.64 |
| 预付款项 | 64,498,282.66 | 49,000,271.93 | 43,540,691.45 | 57,839,165.82 |
| 其他应收款合计 | 76,676,360.78 | 69,061,417.74 | 55,434,569.73 | 21,922,110.74 |
| 存货 | 880,805,703.23 | 743,426,024.3 | 665,411,808.07 | 661,393,912.49 |
| 其他流动资产 | 13,012,277.11 | 33,751,107.89 | 21,801,816.61 | 32,594,508.72 |
| 流动资产合计 | 6,649,180,742.49 | 6,369,176,126.17 | 6,498,493,657.67 | 6,059,552,060.44 |
| 非流动资产: | | | | |
| 长期股权投资 | 102,294,193.23 | 100,538,765.58 | 98,947,043.13 | 97,317,706.9 |
| 其他权益工具投资 | 53,149,740.71 | 53,149,740.71 | 27,991,040.71 | 27,991,040.71 |
| 投资性房地产 | 50,361,989.61 | 50,919,871.74 | 51,470,176.4 | 52,035,702.83 |
| 固定资产 | 1,220,204,283.93 | 1,206,808,225.26 | 1,212,801,665.13 | 1,237,823,397.45 |
| 在建工程 | 298,236,727.84 | 316,710,873.33 | 304,120,978.49 | 309,380,730.34 |
| 使用权资产 | 52,068,770.66 | 48,727,154.05 | 55,540,416.81 | 61,636,729.55 |
| 无形资产 | 227,483,092.71 | 233,285,880.09 | 227,516,683.06 | 232,089,680.26 |
| 开发支出 | 257,060,672.38 | 212,932,644.4 | 176,557,284.48 | 162,316,071.3 |
| 长期待摊费用 | 57,692,367.98 | 74,850,584.42 | 91,922,870.84 | 101,298,807.3 |
| 递延所得税资产 | 43,033,724.7 | 67,389,153.79 | 57,913,935.32 | 55,394,490.36 |
| 其他非流动资产 | 68,923,730.47 | 54,035,900.01 | 65,747,644.83 | 43,169,238.51 |
| 非流动资产合计 | 2,430,509,294.22 | 2,419,348,793.38 | 2,370,529,739.2 | 2,380,453,595.51 |
| 资产总计 | 9,079,690,036.71 | 8,788,524,919.55 | 8,869,023,396.87 | 8,440,005,655.95 |
| 流动负债: | | | | |
| 短期借款 | - | 40,000,000 | 10,000,000 | 15,000,000 |
| 应付票据及应付账款 | 494,548,620.84 | 508,119,418.66 | 614,597,175.97 | 568,352,386.42 |
| 其中：应付票据 | 238,924,131.08 | 243,793,719.29 | 309,487,426.84 | 280,524,622.3 |
| 应付账款 | 255,624,489.76 | 264,325,699.37 | 305,109,749.13 | 287,827,764.12 |
| 合同负债 | 28,068,373.6 | 38,203,845.41 | 26,271,181.95 | 41,528,172.44 |
| 应付职工薪酬 | - | - | - | 3,426,710 |
| 应交税费 | 181,359,832.06 | 210,944,094.15 | 191,479,890.44 | 179,113,942.19 |
| 其他应付款合计 | 184,794,764.45 | 232,193,629.59 | 315,333,003.66 | 234,783,726.4 |
| 一年内到期的非流动负债 | 20,817,318.83 | 19,376,532.21 | 21,491,082.25 | 20,176,705.42 |
| 其他流动负债 | 2,596,190.8 | 3,897,595.15 | 2,334,142.36 | 3,858,988.56 |
| 流动负债合计 | 912,185,100.58 | 1,052,735,115.17 | 1,181,506,476.63 | 1,066,240,631.43 |
| 非流动负债: | | | | |
| 长期借款 | 230,000 | 230,000 | 230,000 | 230,000 |
| 租赁负债 | 25,675,927.04 | 24,496,108.59 | 28,497,713.91 | 33,865,907.19 |
| 预计负债 | 24,635,621.34 | 24,635,621.34 | 24,635,621.34 | 24,635,621.34 |
| 递延收益 | 41,406,697.8 | 41,406,697.8 | 41,406,697.8 | 41,406,697.8 |
| 递延所得税负债 | - | - | - | 111,020.41 |
| 非流动负债合计 | 91,948,246.18 | 90,768,427.73 | 94,770,033.05 | 100,249,246.74 |
| 负债合计 | 1,004,133,346.76 | 1,143,503,542.9 | 1,276,276,509.68 | 1,166,489,878.17 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,015,786,583 | 1,016,176,792 | 1,016,176,792 | 1,016,176,792 |
| 资本公积 | 277,352,051.09 | 281,453,147.68 | 262,769,664.68 | 244,178,189.68 |
| 减:库存股 | 68,300,800.4 | 98,855,937 | 98,855,937 | 98,855,937 |
| 其他综合收益 | 873,251.82 | 873,251.82 | 873,251.82 | 873,251.82 |
| 盈余公积 | 508,088,396 | 508,088,396 | 508,088,396 | 508,088,396 |
| 未分配利润 | 6,370,084,788.26 | 5,964,532,128.93 | 5,930,566,772.91 | 5,629,861,031.98 |
| 归属于母公司股东权益合计 | 8,103,884,269.77 | 7,672,267,779.43 | 7,619,618,940.41 | 7,300,321,724.48 |
| 少数股东权益 | -28,327,579.82 | -27,246,402.78 | -26,872,053.22 | -26,805,946.7 |
| 股东权益合计 | 8,075,556,689.95 | 7,645,021,376.65 | 7,592,746,887.19 | 7,273,515,777.78 |
| 负债和股东权益合计 | 9,079,690,036.71 | 8,788,524,919.55 | 8,869,023,396.87 | 8,440,005,655.95 |
| 公告日期 | 2025-10-25 | 2025-07-30 | 2025-04-19 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |